Market closed
23andMe/ME
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About 23andMe
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
Ticker
ME
Sector
Trading on
Industry
Health Care Providers & Services
Headquarters
Employees
571
Website
23andMe Metrics
BasicAdvanced
$149M
Market cap
-
P/E ratio
-$1.30
EPS
1.21
Beta
-
Dividend rate
Price and volume
Market cap
$149M
Beta
1.21
52-week high
$1.02
52-week low
$0.27
Average daily volume
3.4M
Financial strength
Current ratio
1.524
Quick ratio
1.294
Long term debt to equity
45.425
Total debt to equity
51.68
Management effectiveness
Return on assets (TTM)
-25.77%
Return on equity (TTM)
-154.21%
Valuation
Price to revenue (TTM)
0.717
Price to book
1.04
Price to tangible book (TTM)
1.62
Price to free cash flow (TTM)
-0.975
Growth
Revenue change (TTM)
-32.67%
Earnings per share change (TTM)
81.71%
3-year revenue growth (CAGR)
-7.92%
3-year earnings per share growth (CAGR)
-6.69%
What the Analysts think about 23andMe
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for 23andMe stock.
23andMe Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
23andMe Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
23andMe News
AllArticlesVideos
ME INVESTOR NOTICE: Current 23andMe Holding Co. Shareholders are Notified to Contact BFA Law about Investigation into the Board of Directors (Nasdaq:ME)
GlobeNewsWire·7 days ago
23andMe CEO Wojcicki no longer open to third-party takeover proposals, filing shows
Reuters·1 week ago
ME INVESTOR ALERT: An Investigation into the Board of 23andMe Holding Co. has been Initiated - Current Shareholders are Encouraged to Contact BFA Law
Accesswire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for 23andMe stock?
23andMe (ME) has a market cap of $149M as of October 08, 2024.
What is the P/E ratio for 23andMe stock?
The price to earnings (P/E) ratio for 23andMe (ME) stock is 0 as of October 08, 2024.
Does 23andMe stock pay dividends?
No, 23andMe (ME) stock does not pay dividends to its shareholders as of October 08, 2024.
When is the next 23andMe dividend payment date?
23andMe (ME) stock does not pay dividends to its shareholders.
What is the beta indicator for 23andMe?
23andMe (ME) has a beta rating of 1.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.